KCNJ11 polymorphisms have been linked to the risk of developing type 2 diabetes. Our aim was to define the contribution of KCNJ11 to new-onset diabetes after transplantation (NODAT) among patients treated with Tacrolimus (Tac). A total of 115 NODAT and 205 non-NODAT were genotyped for rs5219 (p.E23K). AA+AG genotypes were significantly associated with NODAT-risk (p=0.004; OR=2.10). The reported effect of this KCNJ11 polymorphism on insulin release by beta cells could explain this association.
Introduction.
New-onset diabetes after transplantation (NODAT) is a frequent complication in patients treated with the immunosuppressive calcineurin inhibitor tacrolimus (tac; FK506) (1, 2) . Patients who receive solid organs require the continuous use of this drug to avoid organ rejection and this, in addition to the increased use of organ transplantation, raised the concerns about NODAT as an important health issue. The search for biological markers to predict the risk of developing NODAT is important to define individualized therapies. Recent studies have identified single nucleotide polymorphisms (SNPs) associated with NODAT-risk among Tac-treated patients (3, 4) .
Among candidate SNPs are those previously linked to the risk of developing type 2 diabetes (DM2) in the general population (5-9).
Recent association studies found a significant association between a KCNJ11 (Kir6.2) SNP (rs5219; E23K) and DM2 (9, 10) . Moreover, activating mutations in KCNJ11 would account for approximately 40% of permanent neonatal diabetes cases (11) .
KCNJ11 encodes a component of the ATP-sensitive potassium (KATP) channel, that in pancreatic beta cells couples glucose metabolism to membrane electrical activity and insulin release (12, 13) . In vitro studies showed that the E23K amino acid change affected the sensitivity toward ATP and insulin release by beta cells (14) .
Based on the reported association of KCNJ11 SNPs and DM2 we hypothesized that this gene could be also implicated in the risk of developing NODAT among Tac-treated patients. To test this hypothesis, we compared the allele/genotype frequencies for several KCNJ11 SNPs between NODAT and no-NODAT patients.
Methods.
Patients. This study was approved by the ethical committee of Hospital Universitario Central Asturias (HUCA), and all the patients signed an informed consent to participate.
The study included 320 Caucasian Spanish patients who received a cadaveric kidney non-NODAT) with the Student´s t and Pearson´s χ 2 tests, respectively. We compared the data at one week, six months and one year posttransplant. A univariate analysis was firstly done to determine which variables were associated with NODAT. A multivariate logistic regression was further used to define whether these variables were independent risk factors for NODAT. A p<0.05 was considered as statistically significant. The statistical power was calculated online (http://statpages.org/proppowr.htm).
Results.
NODAT was significantly associated with patient´s age, BMI, and the rs5219 SNP ( To identify other KCNJ11 variants in linkage disequilibrium with rs5219 that could explain this association, we sequenced the coding exons and flanking intronic nucleotides from 25 NODAT and 25 non-NODAT patients (10 AA, 5 AG, 10 GG in each group) (supplementary figure 2). We found a total of 6 SNPs, all reported in the SNP database (www.ensembl. org; supplementary figure 3 ).
Discussion.
We found a significant association between SNP rs5219 and NODAT. Yang et al. also
found an increased frequency of the risk A allele among NODAT (n=133) compared to non-NODAT (n=170) Hispanic kidney transplant recipients (17) . This polymorphism was previously linked to the risk of developing type DM2 (9, 10). KCNJ11 encodes the kir6.2 subunit of the Potassium inwardly rectifying channel, and the activity of this K+ channel in pancreatic Beta-cells is necessary for insulin secretion (18) . The isoform containing lysine 23 was linked to increased channel opening through nucleoside and decreased sensitivity towards the inhibitory effect of ATP compared to the glutamine 23 (14, 19) . This suggested that E23K could predispose to DM2 by changing the channel's response to the variation of cytosolic nucleotides. In 23 K patients treated with Tac this could lead to induced insulin release and subsequent suppression of insulin transcription and release. It is however possible that this SNP was a surrogate marker for NODATrisk, with other KCNJ11 variants in LD with this SNP being the responsible for the observed association. To answer this question we sequenced the KCNJ11 coding region from several patients. We found six previously reported variants, three of them missense amino acid changes (rs5215, rs1800467, and rs41282930). In agreement with a lack of functional effect, rs5215 (I337K) was not associated with NODAT (14, 19) .
Finally, although our work supported a direct role of rs5219 on NODAT risk among Tac treated patients, we cannot exclude that LD with a variant in a nearby gene could be the responsible for the observed association (20) . Our study also has two main limitations. First, it was based on a limited number of patients (although the sample size was enough to reach a power >80). Second, OGTT was not performed to all the patients and we could thus not exclude that some non DM2 patients could be classified as diabetics based on this test.
In conclusion, we found a significant association between a common KCNJ11 SNP and the risk of developing NODAT among heart and kidney transplanted patients treated with tacrolimus. This polymorphism could be useful to identify patients with an increased risk for NODAT.
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